PDSB
Price
$0.95
Change
+$0.01 (+1.06%)
Updated
Jan 16 closing price
Capitalization
52.06M
67 days until earnings call
Intraday BUY SELL Signals
RGNX
Price
$13.62
Change
-$0.14 (-1.02%)
Updated
Jan 16 closing price
Capitalization
689.49M
44 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PDSB vs RGNX

Header iconPDSB vs RGNX Comparison
Open Charts PDSB vs RGNXBanner chart's image
PDS Biotechnology
Price$0.95
Change+$0.01 (+1.06%)
Volume$530.03K
Capitalization52.06M
REGENXBIO
Price$13.62
Change-$0.14 (-1.02%)
Volume$650.75K
Capitalization689.49M
PDSB vs RGNX Comparison Chart in %
PDSB
Daily Signal:
Gain/Loss:
RGNX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
PDSB vs. RGNX commentary
Jan 18, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PDSB is a Hold and RGNX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 18, 2026
Stock price -- (PDSB: $0.95 vs. RGNX: $13.62)
Brand notoriety: PDSB and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PDSB: 75% vs. RGNX: 95%
Market capitalization -- PDSB: $52.06M vs. RGNX: $689.49M
PDSB [@Biotechnology] is valued at $52.06M. RGNX’s [@Biotechnology] market capitalization is $689.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $111.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PDSB’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • PDSB’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, RGNX is a better buy in the long-term than PDSB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PDSB’s TA Score shows that 5 TA indicator(s) are bullish while RGNX’s TA Score has 3 bullish TA indicator(s).

  • PDSB’s TA Score: 5 bullish, 5 bearish.
  • RGNX’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, PDSB is a better buy in the short-term than RGNX.

Price Growth

PDSB (@Biotechnology) experienced а -11.09% price change this week, while RGNX (@Biotechnology) price change was -6.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was +4.14%, and the average quarterly price growth was +42.40%.

Reported Earning Dates

PDSB is expected to report earnings on Mar 26, 2026.

RGNX is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+1.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($689M) has a higher market cap than PDSB($52.1M). PDSB YTD gains are higher at: 23.578 vs. RGNX (-5.417). PDSB has higher annual earnings (EBITDA): -30.71M vs. RGNX (-120M). RGNX has more cash in the bank: 274M vs. PDSB (26.2M). PDSB has less debt than RGNX: PDSB (18M) vs RGNX (76.5M). RGNX has higher revenues than PDSB: RGNX (161M) vs PDSB (0).
PDSBRGNXPDSB / RGNX
Capitalization52.1M689M8%
EBITDA-30.71M-120M26%
Gain YTD23.578-5.417-435%
P/E RatioN/AN/A-
Revenue0161M-
Total Cash26.2M274M10%
Total Debt18M76.5M24%
FUNDAMENTALS RATINGS
PDSB vs RGNX: Fundamental Ratings
PDSB
RGNX
OUTLOOK RATING
1..100
3071
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
6039
P/E GROWTH RATING
1..100
10021
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PDSB's Valuation (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for RGNX (74) in the Biotechnology industry. This means that PDSB’s stock grew somewhat faster than RGNX’s over the last 12 months.

PDSB's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as RGNX (100) in the Biotechnology industry. This means that PDSB’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's SMR Rating (98) in the Biotechnology industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that RGNX’s stock grew similarly to PDSB’s over the last 12 months.

RGNX's Price Growth Rating (39) in the Biotechnology industry is in the same range as PDSB (60) in the Pharmaceuticals Major industry. This means that RGNX’s stock grew similarly to PDSB’s over the last 12 months.

RGNX's P/E Growth Rating (21) in the Biotechnology industry is significantly better than the same rating for PDSB (100) in the Pharmaceuticals Major industry. This means that RGNX’s stock grew significantly faster than PDSB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PDSBRGNX
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
82%
Momentum
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
83%
MACD
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 10 days ago
84%
Bullish Trend 12 days ago
77%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
Aroon
ODDS (%)
Bearish Trend 6 days ago
87%
Bullish Trend 3 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
PDSB
Daily Signal:
Gain/Loss:
RGNX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GICPX58.170.19
+0.33%
Gabelli Global Growth AAA
ODIIX147.500.46
+0.31%
Invesco Discovery R6
JRSAX12.450.02
+0.16%
JH Adaptive Risk Mgd U.S. Eq A
BRZAX12.980.02
+0.15%
BlackRock Sust Aware Adg Intl Eq Inv A
FMPEX30.89-0.13
-0.42%
Fidelity Advisor Mid Cap Value C

PDSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
+0.70%
AXON - PDSB
43%
Loosely correlated
-0.18%
RGNX - PDSB
41%
Loosely correlated
-1.02%
RXRX - PDSB
40%
Loosely correlated
+0.65%
ALGS - PDSB
38%
Loosely correlated
-3.87%
CLDX - PDSB
37%
Loosely correlated
-0.16%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with BEAM. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
-1.02%
BEAM - RGNX
56%
Loosely correlated
-2.59%
SYRE - RGNX
55%
Loosely correlated
+0.45%
VYGR - RGNX
55%
Loosely correlated
-1.57%
XNCR - RGNX
54%
Loosely correlated
-3.18%
DNLI - RGNX
53%
Loosely correlated
-4.21%
More